KPRX: the cashflow

MyFinsight

For the quarter ending 2025-09-30.

Cash Flow Overview

No enough data to generate the overview

Unit: Dollar

Cash Flow	2025-09-30	2025-06-30
Net (loss) income	-4,318,633	-4,345,439
Depreciation and amortization	14,293	3,741
Research credit receivables	-	414,288
Impairment of intangible assets	0	-
Reduction of operating lease right-of-use assets	75,047	47,364
Stock-based compensation	665,788	411,390
In-process r&d impairment	0	-
Change in fair value of contingent consideration	-1,308,067	412,966
Investment income and fair value adjustments on marketable securities and cash equivalents	-7,064	34,415
Prepaid expenses and other current assets	-747,470	-440,532
Collaboration receivables	612,029	1,816,825
Tax receivables	1,154,482	-17,774
Other assets	32,617	35,502
Accounts payable	469,015	509,579
Accrued expenses	-2,571,553	-2,159,538
Accrued collaboration credit	-945,267	-756,187
Deferred collaboration revenue	1,250,000	1,250,000
Operating lease liabilities	-66,750	-38,785
Net cash (used in) provided by operating activities	-7,780,721	-6,507,633
Purchase of property and equipment	32,626	32,195
Purchases of marketable securities	8,175,851	8,175,851
Sales of marketable securities	305,000	305,000
Maturities of marketable securities	16,981,000	11,240,000
Net cash provided by (used in) investing activities	9,077,523	3,336,954
Gross proceeds from private placement	0	0
Issuance costs for private placement	0	0
Exercise of warrants	265,359	265,359
Proceeds from line of credit	2,750,000	1,000,000
Repayments of line of credit	2,750,000	1,000,000
Net cash provided by financing activities	265,359	265,359
Effect of exchange rate changes on cash, cash equivalents and restricted cash	154,879	141,725
Net increase in cash, cash equivalents and restricted cash	1,717,040	-2,763,595
Cash and cash equivalents at beginning of period	3,796,379	-
Cash and cash equivalents at end of period	5,513,419	-

Unit: Dollar

Time Plot

Show the time plot by selecting a row from the table.

KPRX: the cashflow